Trial Profile

A phase 3, randomized, double-blind, placebo-controlled outcomes study of tecarfarin vs. placebo in patients with End-Stage Renal Disease (ESRD) and Atrial Fibrillation (AFib) not currently treated with chronic oral anticoagulation

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 14 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Nov 2023 According to a Cadrenal Therapeutics media release, company plan to initiate this pivotal trial in 2024.
01 Jun 2023 According to a Cadrenal Therapeutics media release, the company will participate in the 2023 BIO International Convention in Boston.
16 Mar 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com